帕金森病非运动症状的替代疗法:一个小小的回顾
1Department of Neurology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China.
Neuropsychiatric disease and treatment
|December 26, 2024
概括
针和传统中医 (TCM) 等替代疗法在帕金森病 (PD) 的非运动症状 (NMS) 管理方面表现有前途. 需要进一步的研究来验证这些补充治疗方法,以改善患者的生活质量.
科学领域:
- 神经学 神经学
- 综合医学是一个整体的医学.
- 补充疗法 补充疗法
背景情况:
- 帕金森病 (PD) 呈现出显著的非运动症状 (NMS),影响患者的生活质量.
- 目前的治疗方法主要针对运动症状,导致NMS管理不当.
- 替代疗法正在成为PD相关NMS的潜在解决方案.
研究的目的:
- 在帕金森病中全面审查用于管理NMS的替代疗法.
- 分析国际指导方针和中国传统医学 (TCM) 的证据.
- 确定研究缺口,并提出未来的研究方向.
主要方法:
- 文献综述 整合国际指导方针和TCM证据.
- 对PD的替代疗法现有研究的分析NMS.
- 确定研究质量和标准化问题.
主要成果:
- 包括针,认知疗法和TCM在内的替代疗法显示出在PD中管理NMS的潜力.
- 在高质量的随机对照试验 (RCT) 中存在显著差距,特别是在TCM中.
- 结合传统和替代医学的综合方法可以提供个性化的NMS管理.
结论:
- 替代疗法为PD NMS管理提供了有希望的,低副作用的选择.
- 标准化,高质量的研究对于验证这些疗法的有效性至关重要.
- 个性化,综合治疗策略是改善帕金森病患者生活质量的关键.
相关概念视频
Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Parkinson's Disease: Overview
306
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
306
Alzheimer's Disease: Treatment
125
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
125


